Drug Profile


Alternative Names: ACHN-490; Plazomicin sulfate

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Achaogen
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bacteraemia; Nosocomial pneumonia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bacteraemia; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Preclinical Gram-negative infections; Respiratory tract infections; Tularaemia; Yersinia infections

Most Recent Events

  • 22 Feb 2017 Achaogen announces intention to submit MAA to EMA in 2018
  • 13 Dec 2016 Efficacy and adverse events data from the phase III CARE trial in Bacteraemia released by Achaogen
  • 13 Dec 2016 Efficacy and adverse events data from the phase III EPIC trial in Urinary tract infections released by Achaogen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top